pharma · Non-Hodgkin Lymphoma · Advanced Solid Tumors · ADCT
ADC Therapeutics
ADC Therapeutics SA
ADC Therapeutics is a pharma organization headquartered in Lausanne, CH. It trades on NYSE under ticker ADCT. Primary therapeutic focus areas include Non-Hodgkin Lymphoma, Advanced Solid Tumors, Relapsed or Refractory B-
Lausanne, Vaud, Switzerland, CH HQ
2011 Founded
272 Employees
Public company Type
ADCT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Lausanne, Vaud, Switzerland, CH
- Founded
- 2011
- Employees
- 272
- Programs
- 30
- Drugs
- 15
- Patents
- 22
Loncastuximab tesirine
Phase 2 · small molecule · Post-transplant Lymphoproliferative Disorder
Loncastuximab tesirine for Post-transplant Lymphoproliferative Disorder is a Phase 2 program (small_molecule) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Internal code HCI198713
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ADC Therapeutics SA
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Post-transplant Lymphoproliferative Disorder
- Status
- active
- Trials
- 1